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Objective. To compare effects of low- versus high-dose aspirin coadministered with ticagrelor on the reactivity of vascular
smooth muscle cells (VSMCs). Methods. Wistar rats were orally administered ticagrelor (10mg/kg) and/or aspirin (2 or 10mg/kg)
(𝑛=7 per each of 4 groups) or placebo (𝑛=9 )1 2a n d2h o u r sb e f o r ee x p e r i m e n t s .A n t i c o n t r a c t i l ee ff e c t so ft i c a g r e l o r
were assessed in perfusion solution containing ticagrelor (1𝜇M/L). Changes in perfusion pressure proportional to the degree
of adenosine diphosphate analogue- (2-MeS-ADP-) and phenylephrine-induced constriction of rat tail arteries were evaluated.
Results. Pretreatment with high- but not low-dose aspirin enhanced the reactivity of VSMCs only in endothelium-lined vessels.
Suppression of 2-MeS-ADP-induced VSMC contraction by ticagrelor observed in arteries with and without endothelium was
maintained in endothelialized arteries pretreated only with low-dose aspirin. For endothelium-denuded vessels and low-dose
aspirinweobservedasignificantreductionofthemaximaleffectofticagrelorwithnorightwardshiftoftheconcentration-response
curve for phenylephrine. With high-dose aspirin pretreatment ticagrelor exerted no anticontractile effect. Conclusion. High-dose,
but not low-dose, aspirin impairs the anticontractile effect of ticagrelor on ADP-induced VSMC contraction in the rat model. Both
the clinical significance and detailed underlying mechanism of our findings require further investigation.
1. Introduction
Novel platelet P2Y12 receptor inhibitors, prasugrel and tica-
grelor, have successfully overcome many pharmacodynamic
limitationsofclopidogrelandimprovedoutcomesofpatients
with acute coronary syndromes (ACS) [1–4]. Therefore both
ticagrelor and prasugrel have been approved in Europe and
in the United States, and their use in the setting of ACS is
currently recommended by international guidelines [5, 6].
Ticagrelor is a nonthienopyridine, direct P2Y12 blocker
that is more potent than clopidogrel and is associated with
less interindividual variability in pharmacodynamic effect
[7].Furthermore,importantcharacteristicsofticagrelor,such
as rapid onset of action and reversible binding to the P2Y122 BioMed Research International
receptor, may lead to improved outcomes and potentially less
bleeding in the setting of urgent surgery.
Substantial reductions in major adverse cardiovascular
eventsandall-causemortalitywithoutsignificantlyincreased
overall major bleeding complications were observed in the
PLATOtrial,alandmarkphaseIIIstudycomparingticagrelor
withclopidogrelinabroadspectrumofA CSpatients[2].The
unprecedented mortality benefits observed in the PLATO
trial, despite only a moderate decrease in the occurrence of
myocardial infarction, led to a speculation that ticagrelor
therapy was associated with off-target effects [8]. Since P2Y12
receptors were identified on vascular smooth muscle cells
(VSMCs) [9], we and others have earlier demonstrated in
animalandhumanmodelsthatticagrelor,butnotclopidogrel
and prasugrel, prevents ADP-induced VSMC contraction
[10, 11]. Additionally, other groups have demonstrated that
ticagrelor inhibited the uptake of adenosine by human
erythrocytes [12] and also induced the release of adenosine
triphosphate from human erythrocytes, that is, followed by
itsdegradationtoadenosine[13].Theformermechanismwas
proposed to explain the enhancement of adenosine-induced
increase in coronary blood flow observed in a canine model
by ticagrelor [12].
A substantial geographic variation in ticagrelor efficacy
was observed in the PLATO trial [14]. Based on the results
of two independent analyses, it was hypothesized that differ-
encesinthemaintenancedoseofaspirinwereresponsiblefor
this regional difference. In the subgroup of patients treated
with high-dose aspirin (at least 300mg) in the PLATO trial,
particularly in those enrolled in the United States, ticagrelor
therapy was paradoxically associated with worse clinical out-
comes than clopidogrel therapy [14]. As a consequence of
this observation, the US Food and Drug Administration
approved ticagrelor with a “Boxed Warning” indicating that
aspirin daily maintenance doses of above 100mg decrease its
effectiveness [15].
Wecomparedeffectsoflow-doseversushigh-doseaspirin
coadministeredwithticagreloronthereactivityofVSMCsin
ar a tm o d e li nt h i ss t u d y .
2. Materials and Methods
2.1. Animals. The experiments were performed on isolated,
perfusedWistarrattailarteries.Animalswerehousedundera
12hlight/12hdarkcycleandhadunlimitedaccesstofoodand
water.Rats(𝑛=3 7 )weighing250–350gwerepretrea tedwith
investigated drugs (𝑛=7per each of 4 groups) or placebo
(𝑛=9 ), anesthetized by intraperitoneal injection of 120mg
urethane per 1kg of body mass, stunned, and then sacrificed
by cervical dislocation. The study protocol was approved by
theLocalEthicsCommittee,andallexperimentswerecarried
outinaccordancewiththeUnitedStatesNIHguidelines[16].
2.2. Drugs and Solutions. The study drugs (ticagrelor and
aspirin) or placebo (normal saline) was administered orally
12 and 2 hours before the experiment. Similar to previous
studies [10, 11], the doses were ticagrelor (10mg/kg) and
aspirin (2mg/kg or 10mg/kg). The doses of ticagrelor and
aspirin (2mg/kg) were equivalent to typical antiplatelet
doses in human, whereas the dose of aspirin (10mg/kg) was
comparable to the anti-inflammatory and antipyretic dose
used in human studies. Krebs solution contained NaCl
(71.8mmol/L), KCl (4.7mmol/L), CaCl2 (1.7mmol/L),
NaHCO3 (28.4mmol/L), MgSO4 (2.4mmol/L), KH2PO4
(1.2mmol/L), and glucose (11.1mmol/L). All reagents were
purchased from Sigma Aldrich Chemical Company (Poznan,
Poland) and ticagrelor from AstraZeneca Company.
2.3. Study Designand Conduction. Afterdissectionfromsur-
rounding tissues, 2.5 to 3.0cm long segments of rat tail
arterieswerecannulatedandconnectedtoaperfusiondevice.
The distal part was weighted with a 500mg weight, and
the arteries were placed in a 20mL container filled with
oxygenated Krebs solution at 37
∘C. The perfusion pressure
was continuously measured. Perfusion solution flow was
gradually increased up to 1mL/min using a peristaltic pump.
Vesselcontractionsinducedwithphenylephrine(PHE),afull
𝗼1 adrenergic receptor agonist, in the presence of 2-MeS-
ADP (a stable analogue of ADP, 10𝜇M/L) were measured as
an increase in perfusion pressure. The addition of the latter
was a consequence of the results of previously published
studies indicating that 2-MeS-ADP acts on VSMCs as a
partialagonist[10,11,17].Themaximaleffectafterstimulation
with 2-MeS-ADP corresponds to 50–60% of contraction
evoked by 𝗼1 adrenergic receptors stimulation with PHE or
to 60% of contraction induced by KCl (30mM/L) [10, 11].
Additionally,takingintoconsiderationthereversiblebinding
of the P2Y12 receptor by ticagrelor, its effects were assessed
both in its presence (1𝜇M/L) and absence in the perfusion
solution. Experiments were performed separately on control
arteriesandonarteriesderivedfromratspretreatedwithlow-
dose aspirin (2mg/kg) or high-dose aspirin (10mg/kg). The
experiments were performed separately on arteries with and
withoutvascularendotheliuminordertoassesstheroleofthe
vascular endothelium in regulation of vascular tone in arter-
ies derived from rats pretreated with the investigated drugs
(Figure 1).Successfulendotheliumremovalwasconfirmedby
vessel contraction in response to acetylcholine (10
−5 M/L).
2.4. Data Analysis and Statistical Procedures. Concentration-
response curves (CRCs) were calculated according to the van
Rossum method [18]. The maximal response of tissue (𝐸max)
was calculatedasa percentofthemaximalresponseforPHE.
Half maximal effective concentration (EC50)w a se s t i m a t e d
usingclassicalpharmacologicmethodswithpD2 thenegative
logarithm of the EC50.W eu s e dt h en u m b e ro ft h eC R Ca n d
𝐸max in all calculations estimating the statistical significance.
Results were presented as means ± standard deviations.
The Shapiro-Wilk test was used to determine normal distri-
bution of the investigated variables. Statistical analysis was
performed using the Newman-Keuls and ANOVA test for
multiple comparisons of means. A two-sided difference was
considered significant at 𝑃 < 0.05.
3. Results
3.1.EffectofH ighandLowDosesofAspirinontheContractility
of VSMCs. CRCs calculated for arteries with endotheliumBioMed Research International 3
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Figure 1: Flow diagram of study design.
Table 1: Maximal relative response for phenylephrine in relation to the presence of 2-MeS-ADP, ticagrelor and the dose of aspirin in arteries
with vascular endothelium.
𝑛
1 𝐸max [%]
2 𝑃
Control rats: PHE (10𝜇M/L) 20 99.0 ± 2.4
Ticagrelor pretreated rats: PHE (10𝜇M/L) + ticagrelor (1𝜇M/L) +
2-MeS-ADP (10𝜇M/L)
23 79.0 ± 4.7 𝑃 < 0.0001
a
Low-dose aspirin pretreated rats: PHE (10𝜇M/L) 18 99.0 ± 9.8 ns
a
Ticagrelor and low-dose aspirin pretreated rats: PHE (10𝜇M/L) + ticagrelor
(1𝜇M/L) + 2-MeS-ADP (10𝜇M/L)
18 79.0 ± 11.4
𝑃 < 0.0001
a
𝑃 < 0.0001
b
ns
c
High-dose aspirin pretreated rats: PHE (10𝜇M/L) 20 135.0 ± 12.5 𝑃 < 0.0001
a
Ticagrelor and high-dose aspirin pretreated rats: PHE (10𝜇M/L) +
ticagrelor (1𝜇M/L) + 2-MeS-ADP (10𝜇M/L)
20 133.0 ± 11.7
𝑃 < 0.0001
a
𝑃 < 0.0001
c
ns
d
PHE: phenylephrine; 2-MeS-ADP: stable analogue of adenosine diphosphate;
1number of concentration-response curves used for calculations;
2𝐸max:
calculatedasapercentofmaximalresponseforPHE;
a𝑃valuecalculatedversuscontrols;
b𝑃valuecalculatedversusPHE+low-doseaspirin;
c𝑃valuecalculated
versus PHE + ticagrelor + 2-MeS-ADP;
d𝑃 value calculated versus PHE + high-dose aspirin.
derived from rats pretreated with high-dose aspirin were
shifted to the left of control with an increase in the max-
imal response, whereas CRCs obtained for arteries derived
from rats pretreated with low-dose aspirin were comparable
to control (Table 1, Figure 2). EC50 values in arteries with
vascular endothelium calculated for PHE, for rats pretreated
with low-dose aspirin and for rats pretreated with high-dose
aspirin,were7.34(±0.8)×10
−8 M/L,7.33(±1.4)×10
−8 M/L(𝑃
= ns for comparison with controls—7.34 (±0.8) × 10
−8 M/L)
and 2.62 (±1.4) × 10
−8 M/L (𝑃 < 0.0001 for comparison with
controls—7.34 (±0.8) × 10
−8 M/L), respectively. Correspond-
ing pD2 values are presented in Figure 3.
When compared with endothelium-preserved vessels,
CRCs forPHE inendothelium-denudedarteries were shifted
to the left with a significant increase in the maximal re-
sponse. Neither pretreatment with high nor low dose of
aspirin caused any significant shift in comparison with
controls obtained for arteries without vascular endothelium
(Table 2, Figure 4). EC50 values in arteries without vascular
endotheliumcalculatedforPHE,forratspretreatedwithlow-
dose aspirin and for rats pretreated with high-dose aspirin,
were 1.9 (±1.5) × 10
−8 M/L, 2.72 (±1.3) × 10
−8 M/L (𝑃 =
ns for comparison with control arteries without vascular
endothelium—1.9 (±1.5) × 10
−8 M/L) and 2.32 (±0.9) ×
10
−8 M/L(𝑃=nsforcomparisonwithcontrolarterieswithout
vascular endothelium—1.9 (±1.5) × 10
−8 M/L), respectively.
Corresponding pD2 values are presented in Figure 3.
3.2. Effect of Ticagrelor. The second part of our experiment
comparedCRCs for PHE (10
−9–10
−3 M/L) in theabsence and
in the presence of 2-MeS-ADP and ticagrelor. In arteries
with vascular endothelium, CRCs recorded in the presence
of 2-MeS-ADP and ticagrelor showed a rightward shift with
a marked reduction in the maximal response, compared
to control CRCs (Figure 2). EC50 calculated for PHE in
the presence of 2-MeS-ADP and ticagrelor (2.35 (±0.9) ×
10
−7 M/L) was significantly higher than EC50 for controls
(7.34 [±0.8] × 10
−8 M/L; 𝑃 < 0.0001). The inhibitory effect of
ticagrelor was maintained in arteries with endothelial lining
pretreated with low-dose, but not high-dose, aspirin (Table 1,
Figure 2).EC50 valuescalculatedforPHEinthepresenceof2-
MeS-ADP and ticagrelor in arteries pretreated with low- and
high-doseaspirinwere2.03(±0.8)×10
−7 M/L(𝑃 < 0.0001for
comparison with experiments in the absence of ticagrelor—
7.33 (±1.4) × 10
−8 M/L) and 3.50 (±1.5) × 10
−8 M/L (𝑃 =n sf o r
comparison with experiments in the absence of ticagrelor—
2.62 (±1.4) × 10
−8 M/L), respectively. Corresponding pD2
values are presented in Figure 3.
Inexperimentsemployingendothelium-denudedvessels,
we observed a significant reduction of the maximal effect of
ticagrelor without any rightward shift of the concentration-
response curve for phenylephrine for low-dose aspirin while
any anticontractile effect of ticagrelor was absent for high-
dose aspirin (Table 2, Figure 4). EC50 values calculated for
PHE in the presence of 2-MeS-ADP and ticagrelor in arteries4 BioMed Research International
Table 2: Maximal relative response for phenylephrine in relation to the presence of 2-MeS-ADP, ticagrelor and the dose of aspirin in arteries
without vascular endothelium.
𝑛
1 𝐸max [%]
2 𝑃
3
Control rats: PHE (10𝜇M/L) 20 132.0 ± 14.6
Ticagrelor pretreated rats: PHE (10𝜇M/L) + ticagrelor (1𝜇M/L) +
2-MeS-ADP (10𝜇M/L)
20 97.0 ± 15.9 𝑃 < 0.0001
a
Low-dose aspirin pretreated rats: PHE (10𝜇M/L) 21 115.0 ± 12.2 ns
a
Ticagrelor and low-dose aspirin pretreated rats: PHE (10𝜇M/L) + ticagrelor
(1𝜇M/L) + 2-MeS-ADP (10𝜇M/L)
21 90.0 ± 13.7
𝑃 < 0.0001
a
𝑃 < 0.0001
b
ns
c
High-dose aspirin pretreated rats: PHE (10𝜇M/L) 21 125.0 ± 12.1 ns
a
Ticagrelor and high-dose aspirin pretreated rats: PHE (10𝜇M/L) +
ticagrelor (1𝜇M/L) + 2-MeS-ADP (10𝜇M/L)
21 123.0 ± 14.2
ns
a
𝑃 < 0.0001
c
ns
d
PHE: phenylephrine; 2-MeS-ADP: stable analogue of adenosine diphosphate;
1number of concentration-response curves used for calculations;
2𝐸max:
calculatedasapercentofmaximalresponseforPHE;
a𝑃valuecalculatedversuscontrols;
b𝑃valuecalculatedversusPHE+low-doseaspirin;
c𝑃valuecalculated
versus PHE + ticagrelor + 2-MeS-ADP;
d𝑃-value calculated versus PHE + high-dose aspirin.
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Figure 2: Concentration-response curves in arteries with vascu-
lar endothelium obtained for phenylephrine in the absence and
presence of low-dose aspirin, high-dose aspirin, and ticagrelor
coadministeredwith2-MeS-ADP.Pointsandwhiskersdisplaymean
values ± standard deviations. A curve for PHE represents a control
c u rv ef o rT I C ,A S A( L ) ,a n dA S A( H )w h i l ec u rv e sf o rA S A( L )a n d
ASA (H) constitute control curves for ASA (L) + TIC and ASA (H)
+ TIC, respectively. ASA (H): high-dose aspirin; ASA (L): low-dose
aspirin; Ea/Em: % of maximal response; PHE: phenylephrine; TIC:
ticagrelor; 2-MeS-ADP: stable analogue of adenosine diphosphate;
∗aval ueo f𝑃 < 0.05 when comparing the control curve for points of
effect between 20% and 80% of the maximal response.
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Figure3:pD2 valuesinarterieswithandwithoutvascularendothe-
lium obtained for phenylephrine in the absence and presence of
low-dose aspirin, high-dose aspirin, and ticagrelor coadministered
with 2-MeS-ADP. Measurements for phenylephrine alone represent
controls. ASA (H): high-dose aspirin; ASA (L): low-dose aspirin;
E a / E m :%o fm a x i m a lr e s p o n s e ;E C 50: molar concentration pro-
ducing 50% of the maximal response; pD2: negative logarithm of
EC50; TIC: ticagrelor; 2-MeS-ADP: stable analogue of adenosine
diphosphate.
pretreated with low-dose and high-dose aspirin were 3.58
(±1.3) × 10
−8 M/L (𝑃 = ns for comparison with experiments
in the absence of ticagrelor—2.72 [±1.3] × 10
−8 M/L) andBioMed Research International 5
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Figure 4: Concentration-response curves in arteries without vas-
cular endothelium obtained for phenylephrine in the absence and
presence of low-dose aspirin, high-dose aspirin, and ticagrelor
coadministeredwith2-MeS-ADP.Pointsandwhiskersdisplaymean
values ± standard deviations. A curve for PHE represents a control
c u rv ef o rT I C ,A S A( L ) ,a n dA S A( H )w h i l ec u rv e sf o rA S A( L )a n d
ASA (H) constitute control curves for ASA (L) + TIC and ASA (H)
+ TIC, respectively. ASA (H): high-dose aspirin; ASA (L): low-dose
aspirin; Ea/Em: % of maximal response; PHE: phenylephrine; TIC:
ticagrelor; 2-MeS-ADP: stable analogue of adenosine diphosphate;
∗aval ueo f𝑃 < 0.05 when comparing the control curve for points of
effect between 20% and 80% of the maximal response.
2.81 (±1.3) × 10
−8 M/L (𝑃 = ns for comparison with experi-
ments in the absence of ticagrelor—2.32 [±0.9] × 10
−8 M/L),
respectively. Corresponding pD2 values are presented in
Figure 3.
4. Discussion
The main finding of the present study is that high-dose,
but not low-dose, aspirin impairs the vasorelaxant effect
of ticagrelor on the ADP-induced VSMC contraction in
a rat model. This observation provides a new biologically
plausible insight into our knowledge regarding the possible
interaction between ticagrelor and aspirin doses (North
American Paradox). Although the clinical relevance and
detailed underlying mechanism of these findings are yet to
be determined, coronary vasospasm is generally accepted to
frequently accompany atherosclerotic plaque instability and
thrombus formation while ADP constitutes an important
secondary agonist released from activated platelets. ADP-
P2Y12 interaction is suggested to be critical for the sustained
activation of the glycoprotein GP IIb/IIIa receptor and stable
platelet aggregation [4].
In the first part of our study we observed endothelium-
dependent increased reactivity of VSMCs after pretreatment
with high-dose, but not low-dose, aspirin. The concept
linking therapy with nonsteroidal anti-inflammatory drugs
(NSAIDs) with the risk of hypertension or worsening of
preexisting hypertension has been known for almost 20
years [19, 20]. Blood pressure is determined by periph-
eral resistance and cardiac output. The former depends
on vascular tone while natriuresis intensity constitutes an
important factor regulating the latter through changes in
blood volume and subsequently in central venous pressure.
Despite a clear association between NSAIDs use and rise in
blood pressure, the relationship between aspirin and blood
pressure is inconclusive [19–27]. A pooled analysis of five
cohort studies demonstrated an 18% increase in the risk of
hypertension among patients treated with aspirin [21]i n
contrast to the demonstration of an absence of influence of
aspirindoseonbloodpressureintwolargemeta-analyses[19,
20]; moreover, in two other studies, aspirin administered at
bedtimeloweredbloodpressure[22,23].Anothermajorcon-
founding factor precluding any definitive conclusion is the
range of aspirin doses utilized in the aforementioned studies.
F i n a l l y ,r e s u l t so fn u m e r o u st r i a l sa r ei ng e n e r a la g r e e m e n t
such that treatment with low-dose aspirin influences neither
blood pressure nor the efficacy of antihypertensive treatment
[24–27]. Similarly, in our study pretreatment with low-dose
aspirin was not associated with any elevation in the vascular
tone.
The increased reactivity of VSMCs attributed to the
administration of high-dose aspirin in our study may be
causedbytheinhibitionoftheprostanoidsynthesis.NSAIDs,
including aspirin, exert their therapeutic effects by inhibit-
ing cyclooxygenase (COX). Aspirin is believed to exert its
cardioprotective properties through irreversible inhibition
of the platelet COX-1 isoform and subsequent prevention
of the thromboxane A2 synthesis while the COX-2 isoform
remains a target for classical NSAIDs [28]. However, aspirin,
particularly at higher doses, can affect the production of
other prostanoids in various tissues [28]. Prostacyclin acting
through IP receptors exerts opposing biological effects as
compared with thromboxane A2, including vasodilatation,
suppression of VSMC proliferation, and inhibition of platelet
activation. Prostaglandin E2 acts through multiple receptors,
for example, EP1,E P 2,E P 3,E P 4, and IP, and its effects are
more variable. In general, prostaglandin E2 tends to pro-
mote vasodilatation, while at low concentrations it increases
platelet reactivity and at high concentrations inhibits platelet
reactivity [28]. Inhibition of prostacyclin and prostaglandin
E2 synthesis by aspirin may result in vasoconstriction and
sodium and water retention, thus inducing hypertensive
stimuli.
In line with our observations, Aldasoro et al. found
that aspirin at high concentrations and nimesulide, a COX-
2 isoform selective inhibitor, potentiated the contractile
response of gastroepiploic artery to both norepinephrine and
vasopressin while low concentrations of aspirin or SC-560, a
COX-1isoformselectiveinhibitor ,didnotaffecttheresponses6 BioMed Research International
of gastroepiploic artery [29, 30]. Of interest, in other exper-
imental studies, aspirin was simultaneously demonstrated to
relax arterial vessels through an increased nitric oxide release
from the porcine vascular endothelium by direct acetylation
of endothelial nitric oxide synthetase. The latter effect is
independent of COX inhibition [31]a n dt h r o u g hi n h i b i t i o n
of PYK2-mediated RhoA/Rho-kinase activation [32].
Inthesecondpartofourstudyweobservedthatticagrelor
suppresses 2-MeS-ADP-induced VSMC contraction in arter-
ieswithandwithoutendothelium.Thisfactcorrespondswith
a previous report on the identification of P2Y12 receptors on
VSMCs [9].Theinhibitoryeffectofticagrelorwasmaintained
in our study in arteries with endothelial lining pretreated
with low-dose, but not high-dose, aspirin. In experiments
employing endothelium-denuded vessels, low-dose aspirin
treated animals showed a significant reduction of the max-
imal effect of ticagrelor without any rightward shift of the
concentration-response curve for phenylephrine. However,
in high-dose aspirin treated animals, ticagrelor evoked no
anticontractile effect. Our results suggest that an impairment
of the anticontractile effect of ticagrelor by high-dose aspirin
and hyperreactivity of VSMCs after pretreatment with high-
dose aspirin are strongly influenced by the presence of
endothelium. Since the vascular endothelium and VSMCs
produce prostacyclin and, to a lesser extent, prostaglandin
E2 under physiological conditions, we hypothesize that also
the interaction between ticagrelor and high-dose aspirin
observed in our study may be caused by inhibition of
prostanoid synthesis. In line with our hypothesis, FitzGerald
etal.,usingawiderangeofaspirindoses,20–2600mg,proved
that lower doses of aspirin possessed a greater inhibitory
effect on thromboxane A2 than prostacyclin metabolites,
whileincreasingdosesofaspirinsuppressedexcretionofboth
thromboxane A2 and prostacyclin metabolites in healthy
volunteers [33]. Near-complete inhibition of thromboxane
A2 production by low and high doses of aspirin together
with a dose-dependent inhibition of the prostacyclin syn-
thesis was confirmed in other studies of healthy controls or
patientswithatherothromboticdisease[34,35].Additionally,
intracoronaryinfusionofaspirinincreasedcoronaryvascular
resistance and reduced coronary blood flow [36]. Detailed
investigation revealed that intracoronary infusion of aspirin
resulted in the attenuation of both pacing-induced coro-
naryhyperaemiaandflow-mediatedcoronaryarterydilation
[37].Furthermore,recentstudiesdemonstratedthatgenomic
or pharmacological removal of prostacyclin activated both
platelet-dependent and platelet-independent mechanisms
inducing atherogenesis, promoting arterial remodelling, and
triggering plaque instability and thrombosis [38, 39].
Recent data suggested that aspirin produces little
enhancement of platelet inhibition in the presence of strong
P2Y12 receptor blockade [40]. A recent study showed that
ticagrelor is more potent than prasugrel active metabolite in
this regard [41]. Ticagrelor may block the P2Y12-dependent
pathway of platelet aggregation and also sufficiently inhib-
ited platelet aggregation resulting from stimulation with ar-
achidonicacidassuggestedbyBhavarajuetal.[42].Kirkbyet
al. suggested that in platelets the thromboxane A2-dependent
pathway is dependent upon the ADP-P2Y12 pathway both
for the synthesis of thromboxane A2 and fundamentally for
t h ei r r e v e r s i b l ea g g r e g a t i o nt h a tf o l l o w sa c t i v a t i o no ft h e
TP receptors [41]. It has been speculated that addition of
aspirin to a potent P2Y12 receptor antagonist may result in
side effects secondary to inhibition of COX at nonplatelets
sites, thus possibly increasing both bleeding, while providing
littleadditionalantiplateleteffects[41].Thisconceptisinline
with the results of the PLATO trial where the occurrence of
the primary end point was unrelated to aspirin maintenance
dose in the clopidogrel arm [14] suggesting that high-dose
aspirin does not offset the effect of clopidogrel, a moderate
inhibitoroftheP2Y12 receptor.Thequestion,whetheraspirin
provides any additional clinical benefit on top of ticagrelor,
should be addressed in future randomized trials.
Our study has several limitations. First, as in all experi-
mental studies, the relevance of the results needs verification
in the clinical setting. Despite robust statistical techniques
applied by Mahaffey et al., only a randomized study com-
paring the efficacy of ticagrelor and clopidogrel in relation
to aspirin dose could provide a definitive answer. Second,
in-depth determination of the mechanism involved in the
impairment of the anticontractileeffect of ticagrelor by high-
dose aspirin warrants further investigation. Third, we did
not examine the impact of aspirin dosing on other off-target
effects of ticagrelor as they may also contribute to the efficacy
of ticagrelor therapy. Finally, the determination of equivalent
drug exposures in the rat model versus clinically observed
was approximated only.
In conclusion, high-dose, but not low-dose, aspirin
impairs the anticontractile effect of ticagrelor on the ADP-
induced VSMC contraction in an animal model. Both the
clinical significance and detailed underlying mechanism of
our findings require further investigation.
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